DERIVATIVES 4-AMINO-2- (1H-PYRAZOLO [3,4-b] PYRIDIN-3-IL) -6-OXO-6,7-DIHYDRO-5H-PYRROLO [2,3-d] PYRIMIDINE AND THE CORRESPONDING DERIVATIVES ( 1H-INDAZOL-3-ILA) AS CGMP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
The invention relates to compounds of formula (I) or their pharmaceutically acceptable salts, where X, Y, Z, R, R, R, R and the subscripts m, p and q are what is disclosed in the present description. Compounds or their pharmaceutically acceptable salts can modulate in the body the production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the treatment and prevention of diseases that are associated with an impaired cGMP balance, such as cardiovascular disease, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary hypertension (groups I, II, III, IV according to the WHO), angina pectoris, thrombosis, restenosis, myocardial infarction, stroke, cardiac decompensation, fibrosis, le acute hypertension, erectile dysfunction, asthma, acute respiratory distress syndrome (ARDS), chronic renal failure, cystic fibrosis, sickle cell anemia, scleroderma, Raynaud syndrome, diabetes, diabetic retinopathy, liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute pulmonary pulmonary fibrosis or interstitial lung disease. The invention also relates to pharmaceutical compositions which contain the compounds of formula (I) or their pharmaceutically acceptable salts. The invention also relates to compounds or their pharmaceutically acceptable salts for use in the therapy and prophylaxis of the above diseases and for the preparation of pharmaceuticals for this purpose.Изобретение относится к соединениям формулы (I) или их фармацевтически приемлемым солям, где X, Y, Z, R1, R2, R4, Ra и нижние индексы m, p и q представляют собой то, что раскрыто в настоящем описании. Соединения или их фармацевтически приемлемые соли могут модулировать в организме продуцирование циклического гуанозинмонофосфата ("cGMP") и в целом подходят для терапии и профилактики заболеваний, которые связаны с нарушенным балансом cGMP, таких как сердечно-сосудистое заболевание, нарушение эндотелиальной функции, нарушение диастолической
